Cardio Diagnostics
CDIO
35 hedge funds and large institutions have $53.2M invested in Cardio Diagnostics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 35 → 35 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.1% less ownership
Funds ownership: 2.28% → 2.18% (-0.1%)
4% less capital invested
Capital invested by funds: $55.2M → $53.2M (-$2.04M)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCAM
Owl Creek Asset Management
New York
|
+$2.5M |
| 2 |
RL
RPO LLC
Stamford,
Connecticut
|
+$1.44M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$994K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$229K |
| 5 |
OFG
OTA Financial Group
Purchase,
New York
|
+$27.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSU
Mizuho Securities USA
New York
|
-$3.98M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$2.39M |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$647K |
| 4 |
GCL
Glazer Capital LLC
New York
|
-$249K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$178K |
CDIO Hedge Fund Activity: Q3 2022 in Review
35 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Cardio Diagnostics (CDIO) for Q3 2022, worth a combined $53.2M — down 3.7% from $55.2M a quarter earlier.
Fund positioning in CDIO was balanced in Q3 2022: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was Owl Creek Asset Management, opening a new position worth an estimated $2.5M. The largest seller was Mizuho Securities USA, exiting entirely with an estimated $3.98M sold.
- 35 institutional investors held Cardio Diagnostics (CDIO) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $53.2M of Cardio Diagnostics stock for Q3 2022, down 3.7% quarter-over-quarter.
- 3 funds opened new Cardio Diagnostics positions in Q3 2022 and 3 closed out, a net change of 0 holders.
- The largest Cardio Diagnostics buyer in Q3 2022 was Owl Creek Asset Management, an estimated $2.5M added.
- The largest Cardio Diagnostics seller in Q3 2022 was Mizuho Securities USA, an estimated $3.98M sold.
Based on aggregated 13F filings for Q3 2022.